MENU

NEO Stock NeoGenomics (NEO, $9.12) Moving Average Convergence Divergence (MACD) Histogram turned positive on April 9, 2025

A.I.dvisor
at Tickeron.com
Loading...
NEO - NeoGenomics
MACD signal
Bullish Trend
Odds of UP Trend
Tickeron
MACD signal
Price: $9.12
Daily change: +$0.92 (+11.22%)
Daily volume: 3.2M
Capitalization: $1.2B
Industry: Medical Specialties
This is a Bullish indicator signaling NEO's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 44 similar cases where NEO's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

Momentum Indicator for NEO turns positive, indicating new upward trend

NEO saw its Momentum Indicator move above the 0 level on April 14, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned positive. In of the 82 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NEO's RSI Indicator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NEO just turned positive on April 09, 2025. Looking at past instances where NEO's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NEO advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .

NEO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NEO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NEO entered a downward trend on April 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.086) is normal, around the industry mean (23.728). P/E Ratio (49.505) is within average values for comparable stocks, (81.831). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (3.265) is also within normal values, averaging (41.794).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NEO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

View a ticker or compare two or three
NEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of genetic and molecular testing services

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Medical Or Nursing Services
Address
9490 NeoGenomics Way
Phone
+1 239 768-0600
Employees
2100
Web
https://www.neogenomics.com